Vivanza Biosciences Intrinsic Value
Vivanza Biosciences (VIVANZA) median intrinsic value is ₹4.53 from 3 valuation models (range ₹4–₹5), vs current price ₹1.81 — +150.3% upside (Trading Below Calculated Value), margin of safety 60.0%. For current market price and key ratios, visit Vivanza Biosciences stock price NSE.
VIVANZA Valuation Methods Summary — DCF, Graham Number & P/E
Vivanza Biosciences intrinsic value across 3 models vs current price ₹1.81 — upside/downside and value range per method. Browse VIVANZA income statement for revenue, profit, balance sheet and cash flow data.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| Book Value Method | asset | ₹4.53 | ₹4.08 - ₹4.98 | +150.3% | Book Value/Share: ₹10.00, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹3.62 | ₹3.26 - ₹3.98 | +100.0% | Revenue/Share: ₹60.00, P/S: 2.0x |
| Simple DCF (5Y) | dcf | ₹4.53 | ₹3.62 - ₹5.44 | +150.3% | CF Growth: 5.0%, Discount: 15% |
VIVANZA Intrinsic Value vs Market Price — All Valuation Models
Vivanza Biosciences fair value range ₹4–₹5 vs current market price ₹1.81 across 3 valuation models. Also explore VIVANZA share price charts to track price trends across different timeframes.
VIVANZA Intrinsic Value Analysis — Undervalued or Overvalued?
Vivanza Biosciences median intrinsic value ₹4.53, current price ₹1.81 — Trading Below Calculated Value by 150.3%, margin of safety 60.0%.
What is the intrinsic value of VIVANZA?
Based on our comprehensive analysis using 3 different valuation methods, the estimated intrinsic value of Vivanza Biosciences (VIVANZA) is ₹4.53 (median value). With the current market price of ₹1.81, this represents a +150.3% variance from our estimated fair value.
The valuation range spans from ₹3.62 to ₹4.53, indicating ₹3.62 - ₹4.53.
Is VIVANZA undervalued or overvalued?
Based on our multi-method analysis, Vivanza Biosciences (VIVANZA) appears to be trading below calculated value by approximately 150.3%.
VIVANZA Financial Health — Key Ratios vs Industry Benchmarks
Vivanza Biosciences financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 19.00 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Operating Margin | -4.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.09x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
VIVANZA Cash Flow Quality — Operating & Free Cash Flow
Vivanza Biosciences operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹-3 Cr | ₹-3 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹2 Cr | ₹2 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹-1 Cr | ₹-1 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹3 Cr | ₹3 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹-3 Cr | ₹-3 Cr | Negative Cash Flow | 3/10 |